Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · May 20, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment plan called a conditioning regimen for patients with lymphoid malignancies, which are types of blood cancers. Specifically, the study is testing a combination of four medications: fludarabine, busulfan, melphalan, and etoposide. The goal is to see how effective and safe this treatment is for patients preparing to receive a stem cell transplant from a donor.

To participate in this trial, patients need to have a diagnosis of lymphoid malignancies and must have a suitable donor, which could be a sibling, an unrelated person, or a close family member. Participants should also be in relatively good health, meaning they should have a certain level of physical ability and not have severe issues with their liver, kidneys, or heart. If you or someone you know is interested, this trial is actively recruiting, and participants can expect to receive close monitoring throughout the study to ensure their safety and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • lymphoid malignancies
• • donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.
• • patients with ECOG \<3
• Exclusion Criteria:
• • inform consent not provided
• • ECOG \>=3
• • poor liver function (enzyme \>2N or bilirubin \>2N)
• • poor renal function (Scr \>2N)
• • poor cardiac function (EF \<45%)